重组人血管内皮抑素联合GP方案治疗晚期非小细胞肺癌

Efficacy of endostar combined with vinorelbine and cisplatin in treatment of advanced non-small-cell lung cancer

目的探讨我国自主开发的新型重组人血管内皮抑素（恩度）联合化疗的疗效及用药安全性情况。方法 2008年1月~2010年1月海南省人民医院收治的47例晚期非小细胞肺癌（NSCLC）患者。随机分为两组：对照组22例单用GP（吉西它滨＋顺铂）方案治疗;试验组25例,采用GP联合恩度方案治疗。化疗至少2个周期以上。结果单纯化疗组CR为0,PR为31.8%,SD为45.5%,PD为22.7%,RR为31.8%,CBR为77.3%,生活质量改善6例（27.3%）,稳定14例（63.6%）,下降2例（9.1%）;联合化疗组CR为0%,PR为48.0%,SD为40.0%,PD为12.0%,RR为48.0%,CBR为88.0%,生活质量改善11例（44.0%）,稳定13例（52.0%）,下降1例（4.0%）。联合化疗组不良反应发生率比单纯化疗组无明显增加。结论恩度联合GP化疗可以增加晚期NSCLC治疗的有效率,提高生活质量,安全性较好,毒副作用可以耐受。

Aim To observe the efficacy and safety of recombinant human endostatin combined with chemotherapy.Methods From January 2008 to March 2010,47 lung cancer patients were randomly divided into control group consisted of 22 cases treated with gemcitabine＋cisplatin and treatment group consisted of 25 patients treated with endostatin combined with gemcitabine＋cisplatin.Results The CR in control group was 0,PR was 31.8%,SD was 45.5%,PD was 22.7%,RR was 31.8%,CBR was 77.3%.and the life quality of 6 cases were improved（27.3%） 14 cases was stable 963.6%）,and 2 cases worsen（9.1%）.The CR in treatment group was 0%,PR was 48.0%,SD was 40.0%,PD was 12.0%,RR was 48.0%,CBR was 88.0%,in addition the quality of life of 11 cases were improved（44.0%）,13 cases was stable（52.0%）,and 1 cases dropped 94.0%）.The incidence of adverse events was significantly lower in the treatment group than that of the in control group.Conclusions Endostar combined with chemotherapy could improve the efficiency in treatment of lung cancer and the improve the quality of life.